-
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes. Leveraging…
-
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its Phase IIa study for ISM001-055, an in-house generative AI-generated drug candidate for idiopathic pulmonary fibrosis (IPF). The molecule, which targets TNIK (Traf2- and NCK- interacting kinase), has shown a positive safety profile and dose-dependent lung…
-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations
•
MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round, raising hundreds of millions of renminbi. The funding was co-led by Cherami Investment and Shenzhen Capital Group, with participation from Sense Capital and EBI Investment. The capital raised will be directed towards enhancing the company’s…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
-
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
•
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a strategic research collaboration agreement with Inimmune Corporation, a U.S. biotechnology firm specializing in immunotherapy and vaccine innovation. Under the terms of the agreement, Inimmune will utilize Insilico’s proprietary generative AI platform, Chemistry42, to accelerate the…
-
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has entered into a research collaboration with Genetic Leap, a U.S. biotech firm specializing in artificial intelligence (AI) and RNA genetic medicine. This partnership expands on a previously successful pilot and will see Genetic Leap apply…
-
AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million
•
Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered artificial intelligence (AI)-driven drug design and development firm, have announced a definitive agreement to merge. The combined entity will retain the name Recursion, with its headquarters in Salt Lake City, Utah, and will continue to…
-
Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
•
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered into a strategic partnership with Wecomput Technology Co., Ltd, a prominent computational contract research organization (CRO) in China with a global footprint. The collaboration aims to harness the power of artificial intelligence (AI) to enhance…
-
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
•
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. This investigational mRNA drug targets tumors associated with human papillomavirus (HPV), particularly HPV16 and/or HPV18 in the cervix, which are…
-
E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services
•
E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series C financing round. The funding round attracted notable investors such as Ameba Capital, Ventech China, and Borchid Capital. The capital raised is intended to fuel…
-
Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D
•
Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered into a strategic partnership agreement with the government of Tianjin Binhai New Area and fellow Chinese firm Tianjin Yujin Artificial Intelligence Medical Technology Co., Ltd. The collaboration aims to establish an intelligent medical equipment technology…
-
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial…
-
Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation
•
Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China Unicom, aiming to enhance digitalization in enterprise management, product digitization, and global technological empowerment. China Unicom will utilize its network, cloud, communication technology, and AI algorithms to advance the intelligence and digital upgrade of Yuyue’s…
-
GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow UK biotechnology firm Ochre Bio, announcing this week that it will pay up to USD 37.5 million for access to Ochre Bio’s human liver data. This strategic collaboration aims to bolster the development of hepatology…
-
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with artificial intelligence-based technologies provided by Bluecrux, a consulting and technology firm based in Belgium. Bluecrux’s solution consolidates all of Sanofi’s data systems into a unified model, enabling comprehensive end-to-end visibility across the company’s supply chain.…
-
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
•
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic partnership with domestic pharmaceutical firm Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267). The collaboration will combine MindRank’s AI platform technology with Hisun Pharmaceutical’s research and development (R&D) capabilities and manufacturing resources to advance the field…
-
Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI
•
Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US firms Formation Bio and OpenAI to develop customized artificial intelligence (AI) models designed to expedite drug development. While the financial specifics of the agreement were not disclosed, the partnership signifies Sanofi’s strategic commitment to leveraging…
-
Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services
•
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a strategic partnership with Baidu Health. This collaboration aims to focus on AI intelligent outpatient services, thereby strengthening the digital transformation of medical services. The hospital has demonstrated initial success with its AI intelligent outpatient system,…
-
Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse
•
Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with Ruijin Hospital, a Class 3A teaching hospital based in Shanghai. The collaboration aims at developing “Medical digital human metaverse application scenarios,” marking a significant step in the integration of metaverse technology into healthcare. Siemens Healthineers…
